The Role of Leaky Gut in Functional Dyspepsia

Lucas Wauters\textsuperscript{1,2}*, Matthias Ceulemans\textsuperscript{2}, Jolien Schol\textsuperscript{1,2}, Ricard Farré\textsuperscript{2}, Jan Tack\textsuperscript{1,2} and Tim Vanuytsel\textsuperscript{1,2}

\textsuperscript{1} Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, \textsuperscript{2} Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium

Patients with functional dyspepsia (FD) complain of epigastric symptoms with no identifiable cause. Increased intestinal permeability has been described in these patients, especially in the proximal small bowel or duodenum, and was associated with mucosal immune activation and symptoms. In this review, we discuss duodenal barrier function, including techniques currently applied in FD research. We summarize the available data on duodenal permeability in FD and factors associated to increased permeability, including mucosal eosinophils, mast cells, luminal and systemic factors. While the increased influx of antigens into the duodenal mucosa could result in local immune activation, clinical evidence for a causal role of permeability is lacking in the absence of specific barrier-protective treatments. As both existing and novel treatments, including proton pump inhibitors (PPI) and pre- or probiotics may impact duodenal barrier function, it is important to recognize and study these alterations to improve the knowledge and management of FD.

Keywords: functional dyspepsia, permeability, immunology, duodenum, gut-brain-axis

INTRODUCTION

Functional dyspepsia (FD) is a common gastrointestinal (GI) disorder with unknown pathophysiology. According to the Rome IV criteria, two subgroups of FD were proposed: postprandial distress syndrome (PDS) with postprandial fullness or early satiation, and epigastric pain syndrome (EPS) with epigastric pain or burning (Stanghellini et al., 2016). Symptoms must be severe enough to impact on usual activities with a minimal frequency of 1 (EPS) or 3 (PDS) days per week, and be present for the past 3 months with symptom onset at least 6 months before diagnosis (Stanghellini et al., 2016). In contrast, organic dyspepsia may result from erosive esophagitis, peptic ulcer disease or cancer in a minority of patients (Ford et al., 2010; Enck et al., 2017; Ford et al., 2020). While 7–10% of adults fulfilled Rome IV criteria for FD in large internet-based cross-sectional health surveys, organic pathology was not systematically ruled out by endoscopy (Aziz et al., 2018; Sperber et al., 2021), which is expected to be normal in approximately 80% of dyspeptic patients (Ford et al., 2010).

Abbreviations: AJ, adherens junctions; CLDN, claudin; CLE, confocal laser endomicroscopy; CRH, corticotrophin-releasing hormone; DGBI, disorders of gut-brain interaction; DSC, desmocollin; DSG, desmoglein; EoE, eosinophilic esophagitis; EPS, epigastric pain syndrome; Fd4, fluorescein isothiocyanate-labeled 4 kDa dextran; FD, functional dyspepsia; GI, gastrointestinal; IBD, inflammatory bowel disease; IBS, Irritable bowel syndrome; IHC, immunohistochemistry; Isc, short-circuit current; LRP, Lipopolysaccharide-binding protein; LMR, lactulose-mannitol ratio; LPS, Lipopolysaccharide; MUC2, Mucin 2; OCLN, occludin; PD, potential difference; PDS, postprandial distress syndrome; PPI, Proton pump inhibitor; qPCR, quantitative PCR; STAT, Signal transducer and activator of transcription; TEER, transepithelial resistance; TEM, transmission electron microscopy; TJ, Tight junction; ZO, zonula occludens.
Despite the absence of macroscopic alterations during investigation, recent findings point toward microscopic alterations in the duodenal mucosa of FD patients (Wauters et al., 2020b). The duodenum or proximal small intestine has emerged as a key player in disorders of gut-brain interaction (DGBI) as it regulates the passage of food as chyme from the stomach to the small intestine, where nutrients are absorbed (van Baar et al., 2018). Auto- and paracrine mechanisms in the duodenum are also involved in the mucosal defense to acid and luminal digestion of nutrients with secretion of bile and pancreatic juice (Ronnestad et al., 2014). Besides nutrient sensing, passage of luminal content is taking place in the proximal small intestine, which is the most permeable region with the largest intercellular pores of the GI-tract (Camilleri, 2019). Moreover, the small bowel microenvironment allows for a closer interaction between the lumen and host cells in comparison to the colon (Donaldson et al., 2016).

Increased duodenal permeability and immune cell infiltration have been repeatedly reported in FD patients (Wauters et al., 2020b). While the occurrence of duodenal pathology is increasingly recognized, potential luminal (food, acid, bile and the microbiota) or central (stress) causes are still unclear (Wauters et al., 2020a; Wauters et al., 2021c). Duodenal functionality balances between nutrient absorption through an epithelial monolayer on the one hand, while at the same time forming a highly performant barrier that prevents the leakage of luminal content through the epithelium. This is summarized as the delicate but vital balance between intestinal permeability and barrier function (Vanuytsel et al., 2021). In this review, we discuss the different players and measurements of duodenal barrier function and provide a comprehensive overview of studies performed in FD patients, along with potentially associated or causal factors.

**DUODENAL BARRIER FUNCTION**

**Luminal Barrier**

The duodenal barrier is formed by the complementarity of two main elements: the luminal and the tissue compartment (Farré and Vicario, 2017). The luminal compartment comprises various factors, such as bile, gastric acid and pancreatic juice that make the duodenal lumen a hostile environment for micro-organisms (Camilleri, 2019). The first physical barrier that protects the epithelium from toxins and pathogens is the mucus layer, consisting of a mucin glycoprotein network secreted by goblet cells (Figure 1A). The duodenal mucin network is, in contrast to that of the stomach and colon, a loosely and unattached gel-network that separates the lumen from the epithelium (Johansson et al., 2013). The mucus layer is mainly formed by mucin 2 (MUC2), a large and highly glycosylated protein that is abundant in the GI-tract (Johansson et al., 2013). Besides mucins, a variety of antimicrobial peptides is secreted in the mucus layer mainly by Paneth cells in the duodenal crypts, which limit the bacterial residence in the duodenal mucus (Johansson et al., 2013). Antimicrobial factors include secretory immunoglobulin A (sIgA) released by plasma cells, α-defensins by Paneth cells, and β-defensins by epithelial cells (Figure 1A; Camilleri, 2019; Hooper and MacPherson, 2010).

**Cellular Barrier**

The different layers of the duodenal wall constitute the tissue compartment. Enterocytes make up around 80% of the cells of the epithelium (Figure 1A). They function as a physical barrier, regulate nutrient sensing and uptake, and are involved in immunological processes. The enterocyte lining is interspersed with goblet, Paneth, enterochromaffin and microfold or membranous (M-)cells found in the gut-associated lymphoid tissue (GALT) of the Peyer’s patches, which all aid in maintaining the immunological barrier in the duodenum (Camilleri, 2019; Farré and Vicario, 2017). The duodenal wall is highly folded and has numerous villi and crypts to maximize the contact surface with the lumen and increase the absorption of nutrients. Luminal contents can pass the epithelium via different transport routes, depending on their physicochemical properties, of which the paracellular route is the most commonly studied (Farré and Vicario, 2017). Three major cell-to-cell adhesion structures were first described by Farquhar and Palade: tight junctions (TJ), adherens junctions (AJ) and desmosomes (Figure 1B; Farquhar and Palade, 1963). Paracellular transport is strictly controlled to prevent leakage of water and solutes and uncontrolled penetration of luminal substances. This is especially performed by TJ complexes, consisting of the transmembrane proteins occludin (OCLN) and claudins (CLDN), which connect to zonula occludens (ZO) complexes and anchor them to the actin cytoskeleton (Farré and Vicario, 2017; Odenwald and Turner, 2017). The composition and the amount of transmembrane proteins in the TJ determine the permeability of the pores (Shen et al., 2011). While OCLN and ZO are involved in the so-called paracellular leak pathway, the CLDN family regulates the pore pathway as discussed below (Shen et al., 2011; Zuo et al., 2020).

Further downward from the apical side, AJ and desmosomes support the formation of TJ by their adhesive forces (Figure 1B). E-cadherins are integral membrane proteins in epithelial AJ and interact with β-catenin, which in turn is linked to the actin cytoskeleton via α-catenin (Odenwald and Turner, 2017). Desmosomes are comprised of desmoglein (DSG) and desmocollin (DSC), two cadherin-type molecules that link intermediate filaments of adjacent cells via interaction with desmplakin and anchor the epithelium by connecting intermediate filaments to the underlying basal lamina (Farré and Vicario, 2017). Together, these three junctional complexes are important regulators of duodenal integrity. Besides the paracellular route, the transcellular endocytic route is another major but separate pathway and both can be measured using different methodologies.

**MEASURING INTESTINAL PERMEABILITY**

**Functional Assessment: in vivo**

The most common permeability test is the differential urinary sugar excretion test, which consists of a urine collection after
ingestion of sugars which are not metabolized and renally eliminated after intestinal absorption (Camilleri and Vella, 2021). The preferred sugars are mono- (mannitol and rhamnose) and disaccharides (lactulose and sucralose) and the collection period of 0–2 h was validated for the small bowel, as colonic permeability is measured with increasing time (Rao et al., 2011). Besides the lactulose–mannitol ratio (LMR) as a marker of small intestinal permeability, urinary sucrose excretion has been used to measure for gastroduodenal permeability (Table 1; Mujagic et al., 2014). While lactulose and mannitol may be markers for paracellular and transcellular passage, respectively, supporting evidence is lacking (Blomquist et al., 1993). It was also proposed that lactulose passes the intestinal epithelium via the paracellular leak and mannitol via the pore pathway (see “Functional Assessment: ex vivo”), but this concept is controversial (Camilleri, 2019). Large polyethylene glycols (PEG) (>40 kDa) have been used in the past to assess the intestinal permeability in the context of inflammatory bowel diseases (IBD) but these probes are likely to cross the epithelium via the transcellular route based on the high molecular weight (Vanuytsel et al., 2021).

In contrast, the migration of whole commensal bacteria across the intestinal barrier is more likely through transcellular endocytosis in M-cells (Roberts et al., 2010) and enterocytes (Keita et al., 2006; Wu et al., 2014). Lipopolysaccharide (LPS) is located on the surface of Gram-negative bacteria and measured using LPS-binding protein (LBP) as an indication of bacterial translocation. Although markers of epithelial damage such as intestinal fatty acid-binding protein (I-FABP) or locally secreted regulators of intestinal permeability such as zonulin are available (Camilleri and Vella, 2021), the absence of structural defects and methodological limitations of zonulin measurements, respectively, limit their use in FD. Additional in vivo approaches include mucosal admittance or impedance measurements using a tissue conductance meter or endoscopic catheter with electrode sensor at the tip (Ishigami et al., 2017; Komori et al., 2019). Alternatively, duodenal manometry combined with impedance allows determination of baseline impedance following the nocturnal migrating motor complex phase III, thus reducing the potential impact of luminal content (Nakagawa et al., 2020). Finally, confocal laser endomicroscopy (CLE) has been used to identify breaks or extrusion zones in the intestinal epithelium through the passage of intravenously administered fluorescein during endoscopy, which are quantified as epithelial gaps or fluorescein leaks (Nojkov et al., 2020). Although increasingly used, the basolateral to apical flux of fluorescein is less physiological than apical to basolateral passage of luminal compounds (Vanuytsel et al., 2021).

**Functional Assessment: ex vivo**

In contrast to other tissues, epithelia display two special characteristics: tightness and polarity (Vanuytsel et al., 2021). The presence of TJ separates the apical from the basolateral sides of the enterocyte. Polarity is generated by the asymmetric distribution of channels and transporters to either the apical or the basolateral side of the plasma membrane of the enterocyte. These proteins are responsible among others for the absorption of Na\(^+\) and secretion of Cl\(^-\) (Vanuytsel et al., 2021). The gold standard technique for assessing epithelial barrier function is the Ussing chambers, in which the resistance of the epithelium against the passage of ions can be measured by the total transepithelial resistance (R\(_{\text{te}}\), TEER) (Figure 2A). In general, a monolayer of cells is modeled considering two resistors, R\(_{\text{api}}\) (resistance of the apical membrane) and R\(_{\text{bas}}\) (resistance of the basolateral membrane), shunted by a parallel resistor, R\(_{\text{para}}\).
Ohm’s law: \( V = I \times R \)

Then, the resistance can be calculated using the equation:

\[ R = \frac{V}{I} \]

Where \( R \) is the resistance in Ohms, \( V \) is the voltage in Volts, and \( I \) is the current in Amperes.

The TEER measures the net flux of all ions across the epithelium with a high impedance voltmeter and two voltage electrodes. Thus, TEER measures the voltage deflection with the contribution of paracellular (\( R_{\text{para}} \)) and transcellular (\( R_{\text{trans}} \)) resistance. The short-circuit current (Isc) protocol is also used to assess the TEER by applying a constant current to the tissue. Isc is defined as the amount of current per time needed to short-circuit the epithelium and force the potential difference (PD) to be 0 mV. Intermittently, the PD is clamped to values different to 0 mV (voltage clamp) enabling the calculation of the TEER. The Isc reflects the net ion transport movement through the epithelium and can be measured at baseline but also after stimulation with secretagogues such as forskolin (30). Isc measurements are performed when there is an interest of measuring ion transport in the epithelia, mainly the movement of Na\(^+\) and Cl\(^-\).

Alternatively, the Isc can be also estimated in open-circuit by using Ohm’s law, this is what we know as the equivalent Isc. Most commercially available systems provide both open-circuit and voltage clamp protocols. The conductance, as the reciprocal of resistance, can be calculated by two different approaches using Ohm’s law:

\[ G = \frac{1}{R_{\text{eq}}} \]

Where \( G \) is the conductance in Siemens (S), \( R_{\text{eq}} \) is the equivalent resistance in Ohms.

IFABP, intestinal fatty acid-binding protein; IF, immunofluorescence; IHC, immunohistochemistry; Isc, short-circuit current; LMR, lactulose–mannitol ratio; LPS, Lipopolysaccharide; qPCR, quantitative PCR; TEER, transepithelial electrical resistance; TEM, transmission electron microscopy; WB, Western blot.

**Table 1: Techniques and measurements of duodenal barrier function in functional dyspepsia.**

| Type                  | Technique                                      | Measurements                                      |
|-----------------------|------------------------------------------------|---------------------------------------------------|
| Functional (in vivo)   | Differential urinary sugar test                | LMR (0–2 h)sucrose excretion                      |
|                       | Electrical resistance                           | Mucosal admittance or impedance                   |
|                       | Confocal laser endomicroscopy                  | Epithelial gap density (cell extrusion zones)     |
|                       | Blood markers                                   | LPS-binding protein (translocation), IFABP (damage), zonulin (regulator) |
| Functional (ex vivo)   | Ussing chambers                                 | TEER, conductance                                 |
|                       |                                                | Basal ion transport (Isc)                         |
|                       |                                                | Passage or flux:                                  |
|                       |                                                | - paracellular (4–20 kDa labeled dextrans)       |
|                       |                                                | - transcellular (40–80 kDa, bacteria)             |
| Non-functional        | Epithelial integrity: molecular characterization| RNA expression (qPCR, RNA-seq)                    |
|                       |                                                | Protein expression (WB, IHC, IF)                  |
|                       | Epithelial integrity: morphological characterization | TEM                                                |
|                       |                                                | Inflammatory cell death (pyroptosis)              |

**Non-functional Assessments**

Functional alterations of the epithelial barrier function assessed in vivo and ex vivo can be further characterized at molecular level by studying the expression of cell-to-cell adhesion proteins at mRNA and protein levels. We have to be cautious to state, based only on the expression of these genes (molecular biology data), that the epithelial barrier is functionally compromised. In other words, up and downregulation of some cell-to-cell adhesion proteins are not always associated with functional alterations (Weber et al., 2010). Importantly, only TJ proteins directly regulate the paracellular permeability to ions and larger molecules. An altered expression of AJ and desmosomal proteins can influence the expression of TJ proteins but do not directly regulate the paracellular transport. Several studies have used quantitative PCR (qPCR) for TJ (OCLN, CLDN, ZO), AJ (E-cadherin, β-catenin) and desmosomal proteins (DSG, DSC) (Vanheel et al., 2014; Komori et al., 2019; Taki et al., 2019; Nojkov et al., 2020). Also, analysis of protein-expression of cell-to-cell adhesion molecules by western blot (WB) and semi-quantitative evaluation of immunohistochemically (IHC) stained duodenal
biopsies have been done in FD (Vanheel et al., 2014; Du et al., 2018). With the development of next-generation sequencing techniques including RNA-seq, a transcriptomic analysis of whole tissues, including duodenal biopsies, has recently been performed (Puthanmadhom Narayanan et al., 2021b). This included analysis of micro-RNA (miRNA), which may regulate epithelial barrier genes (Puthanmadhom Narayanan et al., 2021a,b).

A structural analysis of the apical junction complex in microvilli is possible but very time consuming using TEM, with assessment of the distance between two adjacent enterocytes, proportions of dilated junctions (>20 nm) and junctions with perijunctional cytoskeleton condensation which blur the intercellular membranes (Puthanmadhom Narayanan et al., 2021b). These measures are, however, not standardized, with different definitions of an altered distance between adjacent enterocytes (up to 30 nm) or lack of separate assessment at the TJ, AJ and desmosomal complexes (Tanaka et al., 2016). Finally, markers of inflammatory cell death or pyroptosis (caspase-1) have been used with IHC to detect potential extrusions of duodenal epithelial cells in response to environmental stimuli (Nojkov et al., 2020).

DUODENAL HYPERPERMEABILITY IN FUNCTIONAL DYSPESIAS

Functional Assessment: in vivo

Studies using differential urinary sugar excretion tests in FD are scarce (Table 2). In pediatric FD patients, a sugar absorption test using lactulose, mannitol and sucrose with a 5 h-urine collection was similar to controls, although the study was only powered to detect a 3-fold difference in LMR (Neilan et al., 2014). In adult FD patients, LMR between 1 and 2 h was greater vs. controls, even after adjusting for anxiety and depression with no difference between PDS and EPS (Puthanmadhom Narayanan et al., 2021b). While the choice for 1–2 h excretion was based on the delayed gastric emptying of liquids in FD, it should be noted that gastric emptying is measured with solids whereas the permeability probe is administered in fasted state and this modification of the technique is not validated (Wauters et al., 2021a). Indeed, previous reports on the same cohort reported no difference in 0–2 h LMR (Desai et al., 2019). Although LMR is not specific for duodenal permeability, a correlation was found with Fd4-passage (see “Functional Assessment: ex vivo”) (Puthanmadhom Narayanan et al., 2021b). Of note, urinary sucrose excretion was similar in dyspeptic Japanese patients (based on Rome III criteria without endoscopy) vs. controls after a 4 h-urine collection (Nakae et al., 2016). It should, however, be noted that sucrose excretion was previously shown to be affected by different drugs (Mujagic et al., 2014).

In adult FD, duodenal mucosal impedance was decreased vs. controls (Ishigami et al., 2017; Komori et al., 2019; Nakagawa et al., 2020). While the consistently lower but gradual increase in baseline impedance from the duodenum to jejunum in FD patients and controls was probably due to a progressive decrease in exposure to luminal content (Nakagawa et al., 2020), a higher epithelial gap density was only present in the distal duodenum of FD vs. controls using CLE (Nojkov et al., 2020). Although these cell extrusions were suggested to allow microbial passage in the duodenum, we found no differences in plasma LBP as a marker of intestinal bacterial translocation in FD (Wauters et al., 2021b). In contrast, mucosal impedance correlated with ex vivo permeability (Nojkov et al., 2020).
TABLE 2 | Impaired duodenal mucosal permeability in adult Functional Dyspepsia patients.

| Findings                                                                 | Methods             | Population                  | Trial details                      |
|--------------------------------------------------------------------------|---------------------|-----------------------------|------------------------------------|
| **In vivo permeability**                                                 |                     |                             |                                    |
| ↑LMR (60–120 min)                                                       | ~ ↑Fd4              | HPLC-MS                     | 39 NUD (16 on-PPI) vs. 24 controls  |
| ↑Mucosal admittance                                                     | tissue conductance  | 21 FD (Rome III, 17 on-PPI) vs. 23 controls |
| ↓Mucosal impedance                                                      | ~ ↓ZO1, IL-1β       | tissue conductance          | 24 FD (Rome III, 12 on-PPI) vs. 20 controls (1 on-PPI) |
| ↓Baseline impedance                                                     | HRM/Z               | 16 FD (Rome IV, 1 Hp-positive) vs. 15 controls |
| ↑Epithelial gap density (D3)                                             | CLE                 | 14 FD (Rome IV, 3 on-PPI) vs. 8 controls |
| **Ex vivo permeability**                                                |                     |                             |                                    |
| ↑Isc (resting and stimulated)                                           | Ussing chambers     | 37 NUD (30 Rome III, 15 on-PPI) vs. 20 controls |
| ↑Fd4-passage, ↓TEER                                                     | Ussing chambers     | 15 FD (Rome III, 6 on-PPI) vs. 15 controls |
| ↑Fd4-passage, ↓bacterial passage                                        | Ussing chambers     | FD                           |                                    |
| ↓TEER                                                                   | ~ Abdominal pain, bloating, IFNγ | Ussing chambers | 10 FD (Rome IV, 3 on-PPI) vs. 10 controls (globus/IDA, 4 on-PPI) |
| ↑Fd4-passage                                                            | Ussing chambers     | 28 FD (Rome IV) vs. 30 controls |
| **Non-functional assessment**                                           |                     |                             |                                    |
| ↓ZO1 (protein)                                                          | p-OCLN ~ ↑ eosinophils, ↑ mast cells, ↓ TEER | qPCR, WB, IF | 15 FD (Rome III, 6 on-PPI) vs. 15 controls |
| ↓OCLN (RNA, protein), p-OCLN (protein)                                  | E-cadherin ~ ↑ mast cells, ↑ eosinophils, ↑ Fd4 | qPCR | 24 FD (Rome III) vs. 20 controls |
| ↑β-catenin (RNA, protein), E-cadherin (protein), DSC2 (RNA, protein)    | RNA-seq             | 39 NUD (32 Rome III, 16 on-PPI) vs. 21 controls |
| ↓ZO1 (RNA)                                                              | ~ ↓Impedance        | qPCR                        | 10 FD (Rome IV, 3 on-PPI) vs. 10 controls (globus/IDA, 4 on-PPI) |
| ↓CLDN1 (RNA)                                                            | IHC                 | 9 FD (Rome III) vs. 9 controls |
| ↑CLDN3 (RNA)                                                            | qPCR                | 35 FD (Rome III, 7 Hp-positive) vs. 31 controls (3 Hp-positive) |
| ↓ZO1, OCLN, CLDN12, CLDN18                                              | RNA-seq             | 39 NUD (32 Rome III, 16 on-PPI) vs. 21 controls |
| ↓E-cadherin, p120 catenin, nectin-3                                     | RNA-seq             | 39 NUD (32 Rome III, 16 on-PPI) vs. 21 controls |
| ↓DSG2, DSC2, plakophilin-2, plakoglobin                                  | RNA-seq             | 39 NUD (32 Rome III, 16 on-PPI) vs. 21 controls |
| ↓Junctions with perijunctional condensation                             | TEM                 | 37 NUD (32 Rome III, 16 on-PPI) vs. 21 controls |
| ↑Intercellular paracellular distance (adherens junction)                | TEM                 | 9 FD (Rome III) vs. 5 controls (1 Hp-positive) |
| ↑Pyroptosis (caspase-1)                                                 | IHC                 | 14 FD (Rome IV, 3 on-PPI) vs. 6 controls (globus/IDA, 4 on-PPI) |
| CLDN, claudin; CLE, confocal laser endomicroscopy; DIS, dilated intercellular spaces; DSC, desmocollin; DSG, desmoglein; Fd4, fluorescein isothiocyanate-labeled 4 kDa dextran; Hp, Helicobacter pylori; HPLC-MS, high-performance liquid chromatography-mass spectrometry; HRM/Z, high-resolution manometry impedance; IDA, iron deficiency anemia; IF, immuno-fluorescence; IFN, interferon; IHC, immuno-histochemistry; IL, interleukin; IHC, short-circuit current; NUD, non-ulcer dyspepsia; OCLN, occludin; PPI, proton pump inhibitor; qPCR, quantitative PCR; TEER, transepithelial electrical resistance; TEM, transmission electron microscopy; WB, Western blot; ZO, zonula-occludens. ~ for correlation, underlined text for significant changes after correction for multiple testing.
permeability (Ishigami et al., 2017), as well as decreased ZO1 and increased IL-1β expression (see "Non-functional Assessments") (Komori et al., 2019). Zonulin was not increased in functional GI patients, which may be related to technical limitations of the assay (Talley et al., 2020). In conclusion, current in vivo measurements do not fully assess duodenal permeability in FD, as demonstrated ex vivo and in vitro and as discussed in the next sections (Figure 3).

**Functional Assessment: ex vivo**
The first study using Ussing chambers showed a lower TEER and higher Fd4-passage in adult FD patients vs. controls (Vanheel et al., 2014). Recently, increased Fd4-passage was confirmed in an independent cohort by our group, with no changes in TEER, which was similar to studies from the United States (Puthanmadhom Narayanan et al., 2021a,b). Indeed, altered epithelial secretion in FD may influence TEER (Puthanmadhom Narayanan et al., 2021a), as the applied current for measuring the generated potential and thus resistance is carried by the common ions Na⁺ and Cl⁻ (Shen et al., 2011). Although decreased TEER was reported by others, the methodology differed and Fd4-passage was not measured (Nojkov et al., 2020). Compared to the lack of association between TEER and in vivo permeability (Nojkov et al., 2020), the importance of Fd4-passage is illustrated by the correlations with in vivo (LMR) and in vitro (intercellular distance and dilated junctions) permeability in FD patients (Puthanmadhom Narayanan et al., 2021b), with the majority of molecular changes pointing to the paracellular leak pathway (see "Non-functional Assessments"). This would indeed suggest an increased paracellular influx of relatively larger molecules into the duodenal mucosa, potentially resulting in immune activation as discussed below.

Increased ex vivo permeability and correlations with (the ratio of) primary and secondary bile salts in FD were found but did not persist after correction for multiple testing (Beeckmans et al., 2020). The lack of correlations between duodenal permeability and (conjugated) bile salts was later confirmed and not unexpected as direct but non-physiological epithelial effects are only expected for (unconjugated) bile acids (Wauters et al., 2021). Indeed, potential cytotoxic effects of hydrophobic bile acids were found in human colonic biopsies and the murine small intestine (Münch et al., 2007; Forsgård et al., 2014), with increased bacterial uptake in patients with collagenous colitis in remission (Münch et al., 2011). In addition to paracellular permeability, increased transcellular passage of bacteria was described in the colonic epithelium of IBS (Bednarska et al., 2017). While this may contribute to recurrence of colonic inflammation in IBS (Münch et al., 2011), similar mechanisms have not yet been shown in the duodenum of FD patients with even lower transcellular duodenal passage of E. coli in FD vs. controls (Beeckmans et al., 2020).

**Non-functional Assessments**
The expression of cell-to-cell adhesion proteins was decreased at the gene and protein level in adult FD patients (Table 2). We previously showed decreased gene and/or protein expression of TJ (ZO1 and OCLN) or AJ (β-catenin and E-cadherin) and desmosomal proteins in FD patients vs. controls (Vanheel et al., 2014). Recently, lower gene-expression of TJ (ZO1, OCLN, CLDN12, and CLDN18) or AJ (E-cadherin, p120 catenin and nectin-3) and desmosomal proteins (DSG2, DSC2, plakophilin-2 and plakoglobin) were confirmed in dyspeptic patients using RNA-seq (Puthanmadhom Narayanan et al., 2021b). In addition, differential expression of 11 miRNAs that regulate epithelial barrier genes was found (Puthanmadhom Narayanan et al., 2021b). Of these, MIR-144, the human equivalent of which was up-regulated in FD patients (Puthanmadhom Narayanan et al., 2021a,b), inhibited the expression of ZO1 and OCLN in a rat model of IBS (Hou et al., 2017). As the decreased gene expression of ZO1 was correlated with duodenal mucosal impedance and Fd4-passage in FD patients (Desai et al., 2019; Komori et al., 2019), these changes suggest involvement of the paracellular leak pathway (Figure 3). In contrast, CLDN transmembrane proteins were unaltered at the gene and protein level (Vanheel et al., 2014; Komori et al., 2019; Taki et al., 2019; Nojkov et al., 2020), except for decreased CLDN1 (Du et al., 2018; Nojkov et al., 2020) and increased CLDN3-expression (Taki et al., 2019). Therefore, involvement of the pore pathway is less likely in the pathophysiology of FD.

Besides molecular changes, structural alterations were found with a lower proportion of junctions with perijunctional cytoskeleton condensation (Puthanmadhom Narayanan et al., 2021b). Moreover, the intercellular distance and proportion of dilated junctions correlated with Fd4-passage and the expression of TJ proteins (Puthanmadhom Narayanan et al., 2021b), also pointing to involvement of the leak pathway (Figure 3). Another study reported dilated junctions at the AJ and not TJ or desmosomes, which correlated with PDS-like symptoms (Tanaka et al., 2016). Interestingly, similar alterations were observed in the jejunum of diarrhea-predominant IBS patients, which correlated with bowel habits and symptoms (Martínez et al., 2013). Increased colonic permeability in IBS was associated with mast cell activation (see “Link With Mucosal Inflammation”) (Martínez et al., 2012; Martínez et al., 2013). In addition, esophageal spongiosis or dilated intercellular spaces, as well as increased in vivo and ex vivo permeability in eosinophilic esophagitis (EoE) correlated with mucosal eosinophils (Warners et al., 2017). As increased small intestinal permeability in active EoE was found by some (Katzka et al., 2015) but not others (Warners et al., 2017), similar interactions with eosinophils may occur in FD as discussed below. Recently, increased inflammatory epithelial cell death or pyroptosis was described, which could account for epithelial gaps measured with CLE (Nojkov et al., 2020). However, associations with other in vivo and ex vivo measurements and validation is lacking.

**FACTORS RELATED TO INTESTINAL PERMEABILITY**

**Link With Mucosal Inflammation**
We have recently reviewed the role of the duodenum in FD, in which we hypothesized that loss of mucosal integrity may lead to
immune activation through antigen presentation with a T-helper type 2 (Th2) response, leading to the infiltration of eosinophils and mast cells (Wauters et al., 2020b). Indeed, we previously found correlations between the reduced protein expression of p-OCLN and E-cadherin with increased eosinophils and mast cells in FD (Vanheel et al., 2014). Although the number and degranulation of duodenal eosinophils were not correlated with \textit{ex vivo} permeability in a follow-up study (Vanheel et al., 2018), under-detection of degranulation is possible using MBP-based methods (Jiménez-Saiz et al., 2020). We also described the Biobreeding (BB)-rat as a spontaneous animal model of DGBI, in which an eosinophil-predominant mucosal inflammation was preceded by increased permeability in the jejunum (Vanuytsel et al., 2014a). Interestingly, the release of MBP from eosinophils decreased the expression of OCLN with decreased colonic barrier function in culture and animal models (Furuta et al., 2005). Similarly, eosinophils have been linked to colonic barrier dysfunction in IBD, which was also present in remission and might exacerbate colonic inflammation (Wallon et al., 2011; Katinios et al., 2020). Therefore, reciprocal interactions exist between eosinophil infiltration and increased permeability in DGBI, IBD as well as EoE as discussed above, suggesting similar mechanisms in the duodenum of FD patients vs. controls (Vanheel et al., 2014; Vanheel et al., 2018), pointing to a potential role in FD. Despite a more heterogeneous cellular profile, no association was found with duodenal permeability (Vanheel et al., 2018). Mast cell-derived tryptase cleaved and activated protease-activated receptor (PAR) 2 on colonocytes, with decreased expression of OCLN and ZO1 and increased \textit{ex vivo} permeability (Jacob et al., 2005). In contrast, no differences in duodenal PAR-expression or correlations with \textit{in vivo} permeability were found in FD patients (Komori et al., 2019). Nevertheless, tryptase and PAR2 may mediate eosinophil migration (Matos et al., 2013) and play a role in FD pathogenesis, as tryptase was also upregulated after duodenal acid infusion in healthy individuals resulting in increased \textit{ex vivo} permeability (Vanheel et al., 2020). Moreover, mast cells were involved in stress-induced small intestinal hyperpermeability (see “Local and Systemic Interactions”) (Vanuytsel et al., 2014b), which was associated with decreased IFN\textsubscript{γ} and increased IL4 expression or Th2-type reactions with eosinophil infiltration in animal models (Yang et al., 2006). In the absence of specific treatments targeting permeability or inflammation, clinical research is, however, limited to associations between duodenal mucosal barrier and immune dysfunction in FD. To the best of our knowledge, the BB-rat is the only available animal model which demonstrates gastric dysmotility, small intestinal hyperpermeability and eosinophilia (Vanuytsel et al., 2014a). Therefore, mechanistic evidence from
preclinical studies with similar alterations to FD patients is lacking as recently reviewed (Accarie and Vanuytsel, 2020).

Local and Systemic Interactions
While no causality or directionality has yet been established between permeability and inflammation, the link with symptoms is likely to be via neuronal changes, as functional and structural neuronal alterations have been described in FD (Cirillo et al., 2015). Besides a correlation between neuronal changes and mucosal eosinophils or mast cells (Cirillo et al., 2015), upregulated glial cell line-derived neurotrophic factor (GDNF) may also play a role in the protection of a disturbed epithelial barrier in FD (Tanaka et al., 2016). In IBS, reactive enteric glial cells have been linked to bacterial translocation in the colon via mast cells with different profiles in health (Meirade-Faria et al., 2021), suggesting a role for neuro-immune interactions. While no link was found between ex vivo permeability and symptoms (Vanheel et al., 2014; Wauters et al., 2021b), the central interactions are complex as illustrated by an inverse association with increased functional and structural connectivity in endogenous pain facilitation regions in IBS patients (Witt et al., 2019). Although similar studies are lacking in FD, increased duodenal permeability (Fd4 passage) was linked with gastric emptying in FD patients (Wauters et al., 2021b), supporting the concept of altered duodenogastric feedback in dyspeptic symptom generation (Wauters et al., 2020b). Moreover, increased gut-homing lymphocytes have been linked with gastric emptying and symptoms in FD (Liebregts et al., 2011). However, duodenal barrier dysfunction has not yet been linked to systemic inflammation and despite increased high-sensitivity CRP, no increase in LBP or duodenal bacterial passage was found in FD (Beeckmans et al., 2020; Wauters et al., 2021b).

Besides a possible role for luminal factors in FD, including duodenal acid and bile (Wauters et al., 2021b), the loss of mucosal integrity may also be triggered by stress-induced activation of immune cells (Zheng et al., 2009). During stress, the hypothalamus is not the only source of corticotropin-releasing hormone (CRH). Intestinal eosinophils produce and release CRH, which activates mast cells and in turn increases intestinal permeability (Zheng et al., 2009). Small intestinal permeability is also increased by intravenous administration of CRH and blocked by pre-treatment with a mast cell stabilizer in healthy students, even after stress (public speech) (Vanuytsel et al., 2014b). CRH was released by mucosal eosinophils and activated mast cells in the colon (Wallon et al., 2008; Wallon et al., 2011), and both were implicated in stress-mediated dysfunction of the jejunum in IBS (Guilarte et al., 2020; Salvo-Romero et al., 2020). Activation of mucosal immune cells with increased permeability is also possible via food or microbial triggers with a role for local IgE-antibodies as a mechanism for food-induced abdominal pain (Aguilara-Lizarraga et al., 2021). Although the potential role of food allergens in FD is still unclear, duodenal mucosal nutrient challenge followed by CLE showed positive reactions in 70% of IBS patients, of which 61% reacted to wheat (Fritscher-Ravens et al., 2019). Changes in permeability include increased CLDN2- and decreased OCLN-expression, as well as an increased intra-epithelial lymphocytes (IEL) and eosinophil degranulation, suggestive of an atypical or non-IgE mediated food allergy (Fritscher-Ravens et al., 2019). Although these mechanisms have not yet been studied in FD, the decreased duodenal p-OCLN-expression was previously correlated with duodenal eosinophils (Vanheel et al., 2014). These findings also point to the involvement of the leak pathway.

EFFECT OF EXISTING AND NOVEL TREATMENTS

Besides acid-suppressive effects of proton pump inhibitors (PPI) as current first-line therapy for FD, we recently described the first prospective evidence for PPI-induced reductions in permeability and inflammation (eosinophils and mast cells) in FD patients (Wauters et al., 2021b). Although the increased duodenal Fd4-passage was normalized after PPI-therapy, only anti-eosinophil and not barrier-protective effects were associated with clinical efficacy of PPI (Wauters et al., 2021b). Besides increased duodenal mucosal permeability and inflammation in FD patients vs. controls off-PPI, similar alterations were found in FD patients with refractory symptoms after >1 month on-PPI (Wauters et al., 2021b). Importantly, no baseline differences in permeability were found between FD patients off- (PPI-naïve) or on-PPI (refractory), illustrating the limitation of cross-sectional studies, which do not account for short- vs. long-term use of PPI (Wauters et al., 2021b). Indeed, previous studies did not assess potential PPI-effects on ex vivo and in vivo permeability prospectively (Vanheel et al., 2014; Komori et al., 2019; Nojkov et al., 2020). We also showed a reduction in salivary cortisol as a marker of stress in FD patients after PPI, with no association between changes in cortisol and Fd4-passage (Wauters et al., 2021b). Although a preclinical study reported that PPI enhanced the stress-induced increase in small intestinal permeability via dysbiosis (Takashima et al., 2020), these findings cannot be translated to patients (Ceulemans et al., 2020). As PPI may influence different factors, including the duodenal microbiome (Wauters et al., 2021c), future studies with more targeted therapies are needed.

Interestingly, a low fiber (<10 g/day) and high simple sugar (>50% of daily carbohydrates) diet triggered functional GI-symptoms with increased duodenal Fd4-passage and decreased microbial diversity in healthy subjects (Saffouri et al., 2019). Moreover, both symptoms and duodenal permeability were linked with decreased bacterial diversity (Saffouri et al., 2019). In addition, a randomized placebo-controlled trial of glutamine supplements showed that the reduction in intestinal hyper-permeability correlated with improved clinical outcomes in diarrhea-predominant IBS patients (Zhou et al., 2019). Although similar effects have not yet been studied in FD, barrier-protective effects of probiotics for NSAID-induced enteropathy were mainly found in the duodenum, suggesting potential benefits (Mortensen et al., 2019). While beneficial effects of L. plantarum strains were found on duodenal mucosal gene transcription, LMR was unaffected after NSAID-administration in healthy volunteers (Mujagic et al., 2017). While no effects were found of a Lactobacillus gasseri strain (LG21) on urinary sucrose excretion
in dyspeptic patients (Nakae et al., 2016), the probiotic \textit{L. casei} LCO1 regulated epithelial permeability through reduced miR-144 and increased OCLN and ZO1 expression (Hou et al., 2020). Interestingly, beneficial \textit{in vitro} effects of gastric acid-resistant endospores on permeability and inflammation may also contribute to the immunological and microbial benefits of \textit{Bacillus coagulans} and \textit{subtilis} strains in FD (Marzorati et al., 2020; Wauters et al., 2021d). Similar to our previous study, no effects on LBP were found with these spore-forming probiotics (Wauters et al., 2021d), even in combination with other pro- and prebiotics in long-term PPI-users (Horvath et al., 2020). Indeed, alterations in FD patients on long-term PPI would justify the search for alternative treatments, including pre- or probiotics.

**CONCLUSION**

Functional dyspepsia is a common disorder with unknown pathophysiology, hampering a conclusive diagnosis and the development of effective drugs. Multiple independent findings using different methods provided evidence for duodenal barrier dysfunction in FD patients. Involvement of the paracellular leak pathway measured in Ussing chambers (Fd4-passage) is further supported by correlations with \textit{in vivo} (LMR) permeability, with decreased expression of TJ-related proteins. As these molecular changes are correlated with increased immune cells, antigen penetration \textit{via} a defective barrier could indeed result in mucosal inflammation. Although associations do not prove causality, both increased permeability and inflammation most likely amplify each other, leading to a vicious circle. In the absence of specific barrier-protective drugs, future studies should include assessment of duodenal permeability in relation to symptoms and treatment of FD.

**REFERENCES**

Accarie, A., and Vanuytsel, T. (2020). Animal models for functional gastrointestinal disorders. \textit{Front. Psychiatry} 11:509681.

Aguiler-Lizarra, J., Florens, M. V., Viola, M. F., Jain, P., Decraecker, L., Appelants, I., et al. (2021). Local immune response to food antigens drives meal-induced abdominal pain. \textit{Nature} 590, 151–156. doi: 10.1038/s41586-020-03118-2

Aziz, I., Palsson, O. S., Törnblom, H., Sperber, A. D., Whitehead, W. E., and Simrén, M. (2018). Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. \textit{Lancet. Gastroenterol. Hepatol.} 3, 252–262. doi: 10.1016/S2468-1253(18)30003-7

Bednarska, O., Walter, S. A., Casado-Bedmar, M., Ström, M., Salvo-Romero, E., Vicario, M., et al. (2017). Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome. \textit{Gastroenterology} 153, 948–960. doi: 10.1053/j.gastro.2017.06.051

Beeckmans, D., Farré, R., Rietherst, D., Keita, A. V., Augustjns, P., Soderén, J. D., et al. (2020). Relationship between bile salts, bacterial translocation, and duodenal mucosal integrity in functional dyspepsia. \textit{Neurogastroenterol Motil.} 32:e13788. doi: 10.1111/nmo.13788

Blomquist, L., Bark, T., Hedenborg, G., Svenberg, T., and Norman, A. (1993). Comparison between the lactulose/mannitol and 51Cr-ethylendiaminetetraacetate acid/14C-mannitol methods for intestinal permeability. Frequency distribution pattern and variability of markers and marker ratios in healthy subjects. \textit{Scand. J. Gastroenterol.} 28, 274–280. doi: 10.3109/030055293099096085

Camilleri, M. (2019). Leaky gut: mechanisms, measurement and clinical implications in humans. \textit{Gut} 68, 1516–1526. doi: 10.1136/gutjnl-2019-318427

Camilleri, M., and Vella, A. (2021). What to do about the leaky gut. \textit{Gut} 2021:428. doi: 10.1136/gutjnl-2021-325428

Ceulemans, M., Wauters, L., Accarie, A., and Vanuytsel, T. (2020). Stress-induced changes in healthy mice do not reflect functional dyspepsia pathophysiology. \textit{Neurogastroenterol Motil.} 32:e13940. doi: 10.1111/nmo.13940

Cirillo, C., Bessisow, T., Desmet, A.-S., Vanheel, H., Tack, J., and Vanden Berghe, P. (2015). Evidence for neuronal and structural changes in submucosal ganglia of patients with functional dyspepsia. \textit{Am. J. Gastroenterol.} 110, 1205–1215. doi: 10.1038/ajg.2015.158

Desai, A., Linden, D. R., Peters, S. A., Chakraborty, S., Halland, M., O’Brein, D., et al. (2019). Impaired duodenal epithelial barrier and secretory functions in non-ulcer dyspepsia. \textit{Gastroenterology} 156, S213–S214.

Donaldson, G. P., Lee, S. M., and Mazmanian, S. K. (2016). Gut biogeography of the bacterial microbiota. \textit{Nat. Rev. Microbiol.} 14, 20–32. doi: 10.1038/nrmicro3552

Du, L., Shen, J., Kim, J. J., He, H., Chen, B., and Dai, N. (2018). Impact of gluten consumption in patients with functional dyspepsia: a case-control study. \textit{J. Gastroenterol. Hepatol.} 33, 128–133. doi: 10.1111/jgh.13813

Enck, P., Azpiroz, F., Boeckxstaens, G., Ellenbruch, S., Feinle-Bisset, C., Holtmann, G., et al. (2017). Functional dyspepsia. \textit{Nat. Rev. Dis. Prim.} 3:17081.

Farquhar, M. G., and Palade, G. E. (1963). Junctional complexes in various epithelia. \textit{J. Cell Biol.} 17, 375–412. doi: 10.1083/jcb.17.3.375

Farré, R., and Vicario, M. (2017). Abnormal barrier function in gastrointestinal disorders. \textit{Handb. Exp. Pharmacol.} 239, 193–217. doi: 10.1007/164_2016_107

Ford, A. C., Mahadeva, S., Carbone, M. F., Lacy, B. E., and Talley, N. J. (2020). Functional dyspepsia. \textit{Lancet} 396, 1689–1702.

Ford, A. C., Marwaha, A., Lim, A., and Moayyedi, P. (2010). What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? systematic review and meta-analysis. \textit{Clin. Gastroenterol. Hepatol.} 8, 830–837. doi: 10.1016/j.cgh.2010.05.031

Forsgård, R. A., Korpela, R., Stenman, L. K., Österlund, P., and Holma, R. (2014). Deoxycholic acid induced changes in electrophysiological parameters and macromolecular permeability in murine small intestine with and without functional enteric nervous system plexuses. \textit{Neurogastroenterol Motil.} 26, 1179–1187. doi: 10.1111/nmo.12383

**AUTHOR CONTRIBUTIONS**

LW wrote the original draft. All authors contributed to the manuscript, revised and approved the final version of the review.

**FUNDING**

JS was supported by the Flanders Research Foundation (FWO Vlaanderen) through a doctoral fellowship (11C4921N). JT was supported by a Methusalem grant of KU Leuven (EZX-C9725-METH/14/05). TV was supported by the Flanders Research Foundation through a senior clinical research mandate (1830517N).
Fritscher-Ravens, A., Pflaum, T., Mösinger, M., Ruchay, Z., Röcken, C., Mill, P. J., et al. (2019). Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E. Gastroenterology 157, 109–118. doi: 10.1053/j.gastro.2019.03.046

Furuta, G. T., Nieuwenhuis, E. E. S., Karhausen, J., Gleich, G., Blumberg, R. S., Lee, J. J., et al. (2005). Eosinophils alter colonic epithelial barrier function: role for major basic protein. Am. J. Physiol. Gastroint. Liver Physiol. 289, G890–G897. doi: 10.1152/ajpgi.00015.2005

Guilarte, M., Vicario, M., Martínez, C., de Torres, I., Lobo, B., Pigrau, M., et al. (2020). Peripheral corticosterin-releasing factor triggers jejunal mast cell activation and abdominal pain in patients with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 115, 2047–2059. doi: 10.14309/ajg.0000000000000789

Hooper, L. V., and MacPherson, A. J. (2010). Immune adaptations that maintain cell activation and abdominal pain in patients with diarrhea-predominant irritable bowel syndrome. Am. J. Physiol. Gastroint. Liver Physiol. 298, G890–G897. doi: 10.1152/ajpgi.00015.2005

Young, A., et al. (2020). Bacillus subtilis HU58 and bacillus coagulans SC208 probiotics reduced the effects of antibiotic-induced gut microbiome dysbiosis in an M-SHIME® model. Microorganisms 8, 1–15. doi: 10.3390/microorganisms8071028

Motos, N. A., Silva, J. F., Matsu, T. C., Damasceno, K. A., Duarte, I. D. G., Lemos, V. S., et al. (2013). Mast cell tryptase induces eosinophil recruitment in the pleural cavity of mice via proteinase-activated receptor 2. Inflammation 36, 1260–1267. doi: 10.1007/s11753-013-9664-5

MeiradeFaria, F., Bednarska, O., Strom, M., Söderholm, I., Walter, S. A., and Keita, A. V. (2021). Colonic paracellular permeability and circulating zonulin-related proteins. Scand. J. Gastroenterol. 56, 424–431. doi: 10.1080/00365521.2021.1879247

Mortensen, B., Murphy, C., O’Grady, J., Lucey, M., Elsafi, G., Barry, L., et al. (2019). Rifaxidibactifer brevB195 protects against small-intestinal damage caused by acetylsalicylic acid in healthy volunteers. Gastroenterology 157, 637–646. doi: 10.1053/j.gastro.2019.05.008

Mujagic, Z., De Vos, P., Boeckx, R., Vos, C., Pieters, H. J. H. M., De Wit, N. J. W., et al. (2017). The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription; A randomized double-blind placebo controlled trial. Sci. Rep. 7:40128. doi: 10.1038/srep40128

Mujagic, Z., Ludidi, S., Keshtehlyi, D., Kesselink, M. A. M., Kruimel, J. W., Lennaerts, K., et al. (2014). Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. Alim. Pharmacol. Ther. 40, 288–297. doi: 10.1111/apt.12829

Münch, A., Söderholm, J. D., Ost, A., Carlsson, A. H., Magnusson, K. E., and Ström, M. (2011). Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission. Alim. Pharmacol. Ther. 33, 954–960. doi: 10.1111/j.1365-2036.2011.04611.x

Münch, A., Ström, M., and Söderholm, J. D. (2007). Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies. Scand. J. Gastroenterol. 42, 1167–1174. doi: 10.1080/00365520701320463

Nakae, H., Tsuda, A., Matsuoka, T., Mine, T., and Koga, Y. (2016). Gastric microbiota in the functional dyspepsia patients treated with probiotic yogurt. BMJ Open Gastroenterol. 3:e000109. doi: 10.1136/bmjgast-2016-001019

Nakagawa, K., Harada, K., Fikree, A., Siddiqi, S., Woodland, P., Masamune, A., et al. (2020). Patients with dyspepsia have impaired mucosal integrity both in the duodenum and jejunum: in vivo assessment of small bowel mucosal integrity using baseline impedance. J. Gastroenterol. 55, 273–280. doi: 10.1007/s00535-019-01614-5

Neilan, N. A., Garg, U. C., Schurman, J. V., and Friesen, C. A. (2014). Intestinal permeability in children/adolescents with functional dyspepsia. BMC Res. Notes 7:275. doi: 10.1186/1756-0500-7-275

Nojok, B., Zhou, S.-Y., Dolan, R. D., Davis, E. M., Appelman, H. D., Guo, X., et al. (2020). Evidence of duodenal epithelial barrier impairment and increased pyroptosis in patients with functional dyspepsia on confocal laser endomicroscopy and “Ex Vivo” mucosa analysis. Am. J. Gastroenterol. 115, 1891–1901. doi: 10.14309/ajg.0000000000000827

Odenwald, M. A., and Turner, J. R. (2017). The intestinal epithelial barrier: a therapeutic target? Nat. Rev. Gastroenterol. Hepatol. 14, 9–21. doi: 10.1038/nrgastro.2016.169

Puthanmadhom Narayanan, S., Linden, D. R., Peters, S. A., Desai, A., Kuwelker, S., O’Brien, D., et al. (2021a). Duodenal mucosal secretory disturbances in functional dyspepsia. Neurogastroenterol. Motil. 33:e13955. doi: 10.1111/nmo.13955

Puthanmadhom Narayanan, S., O’Brien, D. R., Sharma, M., Smyk, T. C., Graham, R. P., Grover, M., et al. (2021b). Duodenal mucosal barrier in functional dyspepsia. Clin. Gastroenterol. Hepatol. 2021:29.
Rao, A. S., Camilleri, M., Eckert, D. J., Buciglio, I., Burton, D. D., Ryks, M., et al. (2011). Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhoea and controls. Am. J. Physiol. Gastro. Liver Physiol. 301, G919–928. doi: 10.1152/ajpgi.00168.2011

Roberts, C. L., Keita, A. V., Duncan, S. H., O’Keeffe, N., Soderholm, J. D., Rhodes, J. M., et al. (2010). Translocation of Crohn’s disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 59, 1331–1339. doi: 10.1136/gut.2009.195370

Rennestad, I., Abika, Y., Kaji, I., and Kaunitz, J. D. (2014). Duodenal luminal nutrient sensing. Curr. Opin. Pharmacol. 19, 67–75. doi: 10.1016/j.coph.2014.07.010

Saffouri, G. B., Shields-Cutler, R. R., Chen, J., Yang, Y., Lektat, H. R., Hale, V. L., et al. (2019). Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat. Commun. 10:2012. doi: 10.1038/s41467-019-09964-7

Salvo-Romero, E., Martínez, C., Lobo, B., Rodiño-Janiero, B. K., Pigrau, M., Sánchez-Chardi, A. D., et al. (2020). Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in diarrhea-predominant irritable bowel syndrome. Sci. Rep. 10:20706. doi: 10.1038/s41598-020-77176-x

Shen, L., Weber, C. R., Raleigh, D. R., Yu, D., and Turner, J. R. (2011). Tight junction pore and leak pathways: a dynamic duo. Annu. Rev. Physiol. 73, 283–309. doi: 10.1146/annurev-physiol-012110-142150

Sperber, A. D., Bangdiwala, S. I., O’Keeffe, N., Ghoshal, U. C., Simren, M., Tack, J., et al. (2021). Worldwide prevalence and burden of functional gastrointestinal disorders results of rome foundation global study. Gastroenterology 160, 99–114. doi: 10.1053/j.gastro.2020.04.014

Stanghellini, V., Chan, F. K. L., Hasler, W. L., Malagelada, J. R., Suzuki, H., Tack, J., et al. (2016). Gastroduodenal disorders. Gastroenterology 150, 1380–1392.

Takashima, S., Tanaka, F., Kagayuchi, Y., Usui, Y., Fujimoto, K., Nadatani, Y., et al. (2020). Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice. Neurogastroenterol. Motil. 32:e13841. doi: 10.1111/nmo.13841

Taki, M., Oshima, T., Li, M., Sei, H., Tozawa, K., Tomita, T., et al. (2019). Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia. Neurogastroenterol. Motil. 31:e13576. doi: 10.1111/nmo.13576

Talley, N. J., Holtmann, G. J., Jones, M., Koloski, N. A., Walker, M. M., Burns, G., et al. (2020). Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity. Gut 69, 1–3. doi: 10.1136/gutjnl-2019-318664

Tanaka, F., Tominaga, K., Fujikawa, Y., Nagami, Y., Kamata, N., Yamagami, H., et al. (2016). Concentration of glial cell line-derived neurotrophic factor correlates positively with symptoms in functional gastrointestinal disease. Dig. Dis. Sci. 61, 3478–3485. doi: 10.1007/s10620-016-4329-5

van Baar, A. C. G., Nieuwdorp, M., Hollema, F., Soeters, M. R., Groen, A. K., and Bergman, J. J. G. M. (2017). Disease activity in eosinophilic esophagitis is associated with impaired esophageal barrier integrity. Am. J. Physiol. Liver Physiol. 313, G2320–G2338. doi: 10.1152/ajpgi.00058.2017

Wauters, L., Burns, G., Ceulemans, M., Walker, M. M., Vanuytsel, T., Keeley, S., et al. (2020a). Duodenal inflammation: an emerging target for functional dyspepsia? Expert. Opin. Ther. Targ. 24, 511–523. doi: 10.1080/14728222.2020.1752181

Wauters, L., Ceulemans, M., and Vanuytsel, T. (2021a). Duodenal barrier and inflammation in dyspepsia: god is in the details. Clin. Gastroenterol. Hepatol. 2021:10. doi: 10.1053/j.gh.2021.11.005

Wauters, L., Ceulemans, M., Frings, D., Lambaerts, M., Accarie, A., Toth, J., et al. (2021b). Proton pump inhibitors reduce duodenal eosinophilia, mast cells and permeability in patients with functional dyspepsia. Gastroenterology 160, 1521–1531. doi: 10.1053/j.gastro.2020.12.016

Wauters, L., Ceulemans, M., Lambaerts, M., Accarie, A., Toth, J., Mols, R., et al. (2021f). Association between duodenal bile salts and gastric emptying in patients with functional dyspepsia. Gut 70, 2208–2210. doi: 10.1136/gutjnl-2020-323598

Wauters, L., Dickman, R., Drug, V., Mulak, A., Serra, J., Enck, P., et al. (2021c). United european gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. United Eur. Gastroenterol. J. 9, 307–331. doi: 10.1002/ueg2.12061

Wauters, L., Slaets, H., De Paepe, K., Ceulemans, M., Wetzelis, S., Geboers, K., et al. (2021d). Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol. Hepatol. 6, 784–792. doi: 10.1016/S2468-1253(21)00226-0

Wauters, L., Talley, N. J., Walker, M. M., Tack, J., and Vanuytsel, T. (2020b). Novel concepts in the pathophysiology and treatment of functional dyspepsia. Gut 69, 591–600. doi: 10.1136/gutjnl-2019-338536

Wauters, L., Tito, R. Y., Ceulemans, M., Lambaerts, M., Accarie, A., Rymanen, L., et al. (2021e). Duodenal dysbiosis and relation to the efficacy of proton pump inhibitors in functional dyspepsia. Int. J. Mol. Sci. 22:13609. doi: 10.3390/ijms222413609

Weber, C. R., Raleigh, D. R., Su, L., Shen, L., Sullivan, E. A., Wang, Y., et al. (2010). Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J. Biol. Chem. 285, 12037–12046. doi: 10.1074/jbc.M109.064808

Witt, S. T., Bednarska, O., Keita, A. V., Icnouncher, A., Jones, M. P., Eisenbruch, S., et al. (2019). Interactions between gut permeability and brain structure and function in health and irritable bowel syndrome. Neurotel. Clin. 21:101602. doi: 10.1152/nic.2018.11.012

Wouters, M. M., Vicario, M., and Santos, J. (2016). The role of mast cells in functional GI disorders. Gut 65, 155–168. doi: 10.1136/gutjnl-2015-309151

Wu, L. L., Peng, W. H., Kuo, W. T., Huang, C. Y., Ni, Y. H., Lu, K. S., et al. (2014). Commensal bacterial endotoxins in epithelial cells is dependent on myosin light chain kinase-activated brush border fanning by interferon-γ. Am. J. Pathol. 184, 2260–2274. doi: 10.1016/j.ajpath.2014.05.003

Yang, P.-C., Jury, J., Söderholm, J. D., Sherman, P. M., McKay, D. M., and Perdue, M. H. (2006). Chronic psychological stress in rats induces intestinal sensitization to luminal antigens. Am. J. Pathol. 168:104. doi: 10.2353/ajpath.2006.050575
Zheng, P.-Y., Feng, B.-S., Oluwole, C., Struiksma, S., Chen, X., Li, P., et al. (2009). Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine. *Gut* 58, 1473–1479. doi: 10.1136/gut.2009.181701

Zhou, Q., Verne, M. L., Fields, J. Z., Lefante, J. J., Basra, S., Salameh, H., et al. (2019). Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. *Gut* 68, 996–1002. doi: 10.1136/gutjnl-2017-315136

Zuo, L., Kuo, W. T., and Turner, J. R. (2020). Tight junctions as targets and effectors of mucosal immune homeostasis. *CMGH* 10, 327–340. doi: 10.1016/j.jcmgh.2020.04.001

**Conflict of Interest:** LW reports financial support for research from Danone and MyHealth; has served on the advisory board of Naturex; has served on the Speaker bureau for Dr. Falk Pharma, Takeda and MyHealth. TV reports financial support for research from Danone, MyHealth, Takeda and VectivBio; has served on the Speaker bureau for Abbott, Dr. Falk Pharma, Fresenius Kabi, Menarini, Remedus, Takeda, Truvion, and VectivBio; reports consultancy fees from Baxter, Dr. Falk Pharma, Takeda, VectivBio, and Zeeland Pharma. JT has given Scientific advice to Adare, AlfaWassermann, Arena, Bayer, Christian Hansen. Clasado, Danone, Devintec, Falk, FitForMe, Grünenthal, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Neurogastrx, Neutec, Novartis, Nutricia, Reckitt Benckiser, Ricordati, Shionogi, Takeda, Truvion, Tsumura, Zealand, and Zeria pharmaceuticals, has received research support from Biohit, Shire, Sofar, and Takeda, and has served on the Speaker bureau for Abbott, Allergan, AstraZeneca, FitForMe, Janssen, Kyowa Kirin, Mayoly, Menarini, Mylan, Novartis, Schwabe Pharmaceuticals, Takeda, Wellspect, and Zeria. All the fundings reported were outside of this study.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wauters, Ceulemans, Schol, Farré, Tack and Vanuytsel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.